This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antibodies Market

Market Insights on Antibodies covering sales outlook, demand forecast & up-to-date key trends

Antibodies Market by Disease Indication (Cardiovascular diseases, CNS disorders, Cancer, Autoimmune Disorders), Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), End User & Region - Forecast to 2021-2031

Antibodies Market Snapshot

Antibodies Market will grow by 21x in upcoming decade, surpassing US$ 601.614 Billion by the end of 2031, finds Future Market Insights (FMI).

North America is anticipated to dominate the Antibodies Market holding around 45.8% of the overall market share in 2021. The growth can be attributed to rising awareness, increasing government funding to find treatment for chronic ailments and presence of leading market players in U.S. and Canada.

FMI also states that, F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., and Bristol-Myers Squibb Company are leading players operating in the antibodies market. Collectively they will account for 3 out of 4 sales of antibodies across the globe.

Customize this Report

Let us know your requirement to get
100% FREE customization

Antibodies Market - Key Points Covered in Study

  • Antibodies Market estimates and forecast 2021 – 2031
  • Key drivers and restrains impacting Antibodies Market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competitive Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact On Antibodies Market and How to Navigate
  • Recommendation on Key Winning Strategies

Antibodies Market Outlook In Comparison to 2021 – 2031 Forecast

Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various type neurological diseases. Certain type of antibodies called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by vaccinia virus. Rising cases of viral infection will drive the demand for antibodies.

National Stem Cell Foundation (NSCF) has reported that about 4% of global population is affected by some kind of autoimmune diseases. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease and rheumatoid arthritis.

Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in upcoming years.

In April 2021, Xencor commenced its Phase I clinical trial of its new engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing treatment of patients with autoimmune diseases.

The COVID-19 pandemic boosted the demand for antibodies as patients suffering from COVID-19 were highly susceptible to contracting various other ailments and in some cases triggered the autoimmune diseases in the patient.

Zydus Cadila is planning to launch its own antibody cocktail, ZRC-3308, through trials in India. The antibody cocktails are used in COVID-19 patients who are at risk of progressing to severe disease.

Novel biosimilar antibodies manufacturers are slashing their prices to compete with branded antibodies manufacturers especially in European market. With expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Antibodies Market Download Report Brochure

How do Research and Development Activities Impact Antibodies Sales Outlook?

Surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies are driving the market growth.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.

In September 2020, Regeneron collaborated with Roche for efficient clinical trials of their monoclonal antibody treatment (REGN-COV2) for COVID-19.

Rising cases of multiple sclerosis and Parkinson’s disease among older population is key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, and novel and effective treatments in middle income countries. This is expected to positively influence the sales of antibodies.

In 2021, Berkeley Lights, a digital cell biology company joined hands with Genovac, an antibody discovery company to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Considering this, the rising application of antibodies in chronic diseases treatment will create scope for market expansion in the near future.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Is Increasing Production of Bio-similar Antibodies driving Demand?

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies and they have very few side effects.

In 2020, Johnson and Johnson reported US$ 3.75 Bn achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade generated US$ 659 Mn in 2020.

U.S. Food and Drug Administration (FDA) approved a biosimilar of Remicade called “Avsola” in December 2019, and are now eligible for producing biologics product all over the world.

Increasing demand for biosimilar antibodies in treatment of rheumatoid arthritis along with high patient acceptance rate will boost the market growth.

One of the leaders in prescription medicines, Pfizer received the EU approval for biosimilar antibody therapeutics “Amsparity” for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020.

Elevated new drug approval rates and products in the clinical trials in pharmaceutical companies will drive the market in upcoming years.

Antibodies Market Country-wise Analysis

Why Is U.S Dominating The Global Antibodies Market?

The U.S. is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and presence of leading market players in the country. Increasing purchasing power of consumers along with increasing government funding will drive the market growth.

National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in U.S. grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country will further increase the demand for antibodies.

National Stem Cell Foundation (NSCF) states that, autoimmune diseases are the third most common reason of chronic ailments in U.S. Increasing cases of diabetes and multiple sclerosis in the country will positively influence the demand for antibodies.

In February 2021, U.S. Food and Drug Administration (FDA) issued the authorization for bamlanivimab and etesevimab monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients suffering for SARS-CoV-2 and are succeptible to progressing to severe case. This will accelerate the demand for antibodies in the country for years to come.

What Are The Factors Driving Antibodies Demand In Saudi Arabia?

GCC countries led by Saudi Arabia is emphasizing on early diagnosis and screening of cancer to elevate the survival rate and chance of successful treatment. Increasing screening and diagnosis using biosimilar antibodies therapeutics will bode well with market growth in the region.

Around 1291 new cases of childhood cancer were reported in Saudi Arabia in 2020, as per the report from World Health Organization (WHO). Increasing establishment of biotechnology research and development centers to develop cancer monoclonal antibodies will drive the market growth in upcoming years.

Market Players are working towards developing antibodies which are effective in treating COVID-19. Biotech company SaudiVax and U.S. firm Abound Bio jointly announced a licensing agreement for developing COVID-19 treatment.

The companies discovered a human monoclonal antibodies showcasing high potency in neutralizing activity against SARS-CoV-2. This will create growth opportunities in Saudi Arabia.

How Will Antibodies Market Growth Unfold in China?

World Bank evaluated that the healthcare expenditure in China was accounted for 5.35% of its gross domestic product (GDP) in 2018. Rising geriatric population and associated ailments will drive the market growth in upcoming years.

Development and production of antibodies in China is expected to increase significantly owing to increasing government investment towards drugs development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer and infections.

Chine developed its first U.S. Food and Drug Administration (FDA) approved antibody in March 2018.The antibody named “Trogarzo” was useful in treating resistant HIV infections. Similarly more than ten other China made biologics are under clinical trials.

The government also started a “Chinese Antibody Society” with the aim to assist in speedy FDA approval as well as ensure effective marketing of China made antibody-based therapeutics.

These initiatives are expected to reflect positively on the China market, presenting conducive environment for the growth of antibodies sales.

What is Influencing Antibodies Market Growth In India?

Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with development of healthcare system in the country.

As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. Surge in cancer patients will drive the demand for monoclonal antibodies for cancer treatment.

Antibodies are finding its use in developing treatment for ongoing COVID-19 pandemic. World Health Organization has reported that around 29.97 million people were infected with COVID-19 in India as of June 2021. These numbers indicate huge potential for monoclonal antibodies market in India.

In 2021, Roche collaborated with Cipla to provide monoclonal antibody drugs called “REGEN-COV2”. REGEN-COV2 is a cocktail of monoclonal antibodies casirivimab and imdevimab and has received strict medical emergency approval.

Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare will create opportunities for growth in India.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Antibodies Market Category-wise Insights

Why Are Cancer Antibodies Gaining Popularity?

Rising prevalence of non-Hodgkin lymphoma and other type of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With focus on cancer research increasing, the antibodies market outlook for the upcoming decade will remain positive.

Which Product Will Register High Demand?

Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category will rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in geriatric population across the globe. The rising demand for effective treatment of aforementioned chronic ailments will remain a chief growth driver in this category.

Who is the Leading End User of Antibodies?

Hospitals are expected to generate highest demand throughout the forecast period. Growing pool of patients and faster accessibility to healthcare will elevate the demand in Hospitals.

Hospitals around the world register a higher footfall of patients as they offer expert care and infrastructure required for administering necessary treatment. Antibodies demand in hospitals multiplied amid COVID-19 outbreak.

Even as governments roll out vaccination drives to contain the pandemic, hospitals will remain dominant end user on account of rising cases of various types of chronic ailments.

Antibodies Market - Competitive Landscape

Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long acting antibody drugs to reduce healthcare cost.

In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic merger and acquisition for portfolio expansion is in the cards as well.

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment “iptacopan”, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that, during 12 weeks of iptacopan monotherapy treatment no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

In August 2020, Johnson & Johnson entered into final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Bn. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition will allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth through expansion into autoantibody-driven disease.

Antibodies Market – Report Scope

Attribute

Details

Forecast Period

2021 – 2031

Historical Data Available for

2016 – 2026

Market Analysis

US$ Mn for Value & Units for Volume

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Key Segments Covered

By Disease Indication, End user, Product Type, Region

Key Companies Profiled

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Sanofi SA
  • Eli Lilly and Co.

Report Coverage

Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis

Customization & Pricing

Available upon Request

Key Segments Covered in Antibodies Market Study

By Disease Indication

  • Cardiovascular diseases
  • CNS disorders
  • Cancer
  • Autoimmune Disorders

By Product Type

  • Monoclonal antibodies
  • Polyclonal antibodies
  • Antibody-drug complexes (ADCs) 

By End User

  • Hospitals
  • Long-term Care Facilities
  • Research institutes

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa (MEA)

Frequently Asked Questions

Driven by increasing research in monoclonal antibodies in treating autoimmune disease, the antibodies market size is forecast to reach US$ 186.865 Billion in 2021.

Between 2016 and 2020, the antibodies market grew at 9.50% CAGR owing to increasing cases of cancer and diabetes in last 5 years.

The market valuation of antibiotics is forecast to reach US$ 601.607 Billion by the end of 2031.

U.S., Switzerland, and France are leading producers of the antibodies owing to presence of leading market players and dedicated research facilities in these countries.

Demand registered in North America will continue rising, backed by presence of leading market players in the U.S. and Canada, the North America market is predicted to account for 49.2% market share by 2031.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services Inc., Amgen Inc., and Bristol-Myers Squibb Company are the top five companies operating in the market.

Top five players account for nearly 75% of the antibodies market in 2021.

Antibodies sales will increase at 11.3% CAGR in Europe, backed by rising demand in the U.K., Germany and other countries.

Leading countries driving demand in the antibodies market are U.S., Japan, China, U.K., and Canada.

As of 2021, Japan and China holds around 10.3% and 4.3% share respectively in the global antibodies market.

Table of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Antibodies Market Overview

    4.1. Introduction

        4.1.1. Antibodies Market Definition

        4.1.2. Antibodies Market Taxonomy

        4.1.3. Antibodies Market Product Type Overview

        4.1.4. Overview

    4.2. Antibodies Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Regulations

5. Global Antibodies Market Forecast

    5.1. Market Value (US$ Mn) Forecast

        5.1.1. Y-o-Y Growth Projections

        5.1.2. Absolute $ Opportunity

    5.2. Antibodies Market Trends

        5.2.1. Market Share, By Region

        5.2.2. Market Share, By Product Type

        5.2.3. Market Share, By End User 

        5.2.4. Market Share, By Disease Indication

6. Global Antibodies Market Analysis, By Product Type

    6.1. Introduction

        6.1.1. Y-o-Y Growth Comparison, By Product Type

        6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type

    6.2. Market Forecast, By Product Type

        6.2.1. Monoclonal antibodies

            6.2.1.1. Absolute $ Opportunity

            6.2.1.2. Market Value (US$ Mn) Forecast

        6.2.2. Polyclonal antibodies

            6.2.2.1. Absolute $ Opportunity

            6.2.2.2. Market Value (US$ Mn) Forecast

        6.2.3. Antibody-drug complexes (ADCs)

            6.2.3.1. Absolute $ Opportunity

            6.2.3.2. Market Value (US$ Mn) Forecast

        6.2.4. Market Attractiveness Analysis, By Product Type

        6.2.5. Prominent Trends

7. Global Antibodies Market Analysis, By Disease Indication

    7.1. Introduction

        7.1.1. Y-o-Y Growth Comparison, By Disease Indication

        7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

    7.2. Market Forecast, By Disease Indication

        7.2.1. Cardiovascular diseases

            7.2.1.1. Absolute $ Opportunity

            7.2.1.2. Market Value (US$ Mn) Forecast

        7.2.2. CNS disorders

            7.2.2.1. Absolute $ Opportunity

            7.2.2.2. Market Value (US$ Mn) Forecast

        7.2.3. Cancer

            7.2.3.1. Absolute $ Opportunity

            7.2.3.2. Market Value (US$ Mn) Forecast

        7.2.4. Autoimmune Disorders

            7.2.4.1. Absolute $ Opportunity

            7.2.4.2. Market Value (US$ Mn) Forecast

        7.2.5. Market Attractiveness Analysis, By Disease Indication

        7.2.6. Prominent Trends

8. Global Antibodies Market Analysis, By End User 

    8.1. Introduction

        8.1.1. Y-o-Y Growth Comparison, By End User 

        8.1.2. Market Share & Basis Point (BPS) Analysis, By End User 

    8.2. Market Forecast, By End User

        8.2.1. Hospitals

            8.2.1.1. Absolute $ Opportunity

            8.2.1.2. Market Value (US$ Mn) Forecast

        8.2.2. Long-term Care Facilities

            8.2.2.1. Absolute $ Opportunity

            8.2.2.2. Market Value (US$ Mn) Forecast

        8.2.3. Research institutes

            8.2.3.1. Absolute $ Opportunity

            8.2.3.2. Market Value (US$ Mn) Forecast

        8.2.4. Market Attractiveness Analysis, By End User 

        8.2.5. Prominent Trends

9. Global Antibodies Market Analysis, By Region

    9.1. Introduction

        9.1.1. Y-o-Y Growth Projections, By Region

        9.1.2. Market Share & Basis Point (BPS) Analysis, By Region

    9.2. Market Forecast, By Region

        9.2.1. North America Market Value (US$ Mn) Forecast

        9.2.2. Latin America Market Value (US$ Mn) Forecast

        9.2.3. Western Europe Market Value (US$ Mn) Forecast

        9.2.4. Eastern Europe Market Value (US$ Mn) Forecast

        9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast

        9.2.6. Japan Market Value (US$ Mn) Forecast

        9.2.7. MEA Market Value (US$ Mn) Forecast

    9.3. Regional Attractiveness Analysis

10. North America Antibodies Market Analysis

    10.1. Introduction

        10.1.1. Y-o-Y Growth Projections, By Country

        10.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    10.2. Key Regulations

    10.3. Key Trends

    10.4. North America Market Forecast

        10.4.1. Market Value (US$ Mn) Forecast, By Country

            10.4.1.1. S. Absolute $ Opportunity

            10.4.1.2. Canada Absolute $ Opportunity

        10.4.2. Market Value (US$ Mn) Forecast, By Product Type

            10.4.2.1. Monoclonal antibodies 

            10.4.2.2. Polyclonal antibodies 

            10.4.2.3. Antibody-drug complexes (ADCs) 

        10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            10.4.3.1. Cardiovascular diseases 

            10.4.3.2. CNS disorders 

            10.4.3.3. Cancer

            10.4.3.4. Autoimmune Disorders

        10.4.4. Market Value (US$ Mn) Forecast, By End User

            10.4.4.1. Hospitals

            10.4.4.2. Long-term Care Facilities

            10.4.4.3. Research institutes

        10.4.5. Market Attractiveness Analysis

            10.4.5.1. By Country

            10.4.5.2. By Product Type

            10.4.5.3. By End User 

            10.4.5.4. By Disease Indication

        10.4.6. Drivers & Restraints: Impact Analysis

11. Latin America Antibodies Market Analysis

    11.1. Introduction

        11.1.1. Y-o-Y Growth Projections, By Country

        11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    11.2. Key Regulations

    11.3. Key Trends

    11.4. Latin America Market Forecast

        11.4.1. Market Value (US$ Mn) Forecast, By Country

            11.4.1.1. Argentina Absolute $ Opportunity

            11.4.1.2. Brazil Absolute $ Opportunity

            11.4.1.3. Mexico Absolute $ Opportunity

            11.4.1.4. Rest of Latin America Absolute $ Opportunity

        11.4.2. Market Value (US$ Mn) Forecast, By Product Type

            11.4.2.1. Monoclonal antibodies 

            11.4.2.2. Polyclonal antibodies 

            11.4.2.3. Antibody-drug complexes (ADCs) 

        11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            11.4.3.1. Cardiovascular diseases 

            11.4.3.2. CNS disorders 

            11.4.3.3. Cancer

            11.4.3.4. Autoimmune Disorders

        11.4.4. Market Value (US$ Mn) Forecast, By End User

            11.4.4.1. Hospitals

            11.4.4.2. Long-term Care Facilities

            11.4.4.3. Research institutes

        11.4.5. Market Attractiveness Analysis

            11.4.5.1. By Country

            11.4.5.2. By Product Type

            11.4.5.3. By End User 

            11.4.5.4. By Disease Indication

        11.4.6. Drivers & Restraints: Impact Analysis

12. Western Europe Antibodies Market Analysis

    12.1. Introduction

        12.1.1. Y-o-Y Growth Projections, By Country

        12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    12.2. Key Regulations

    12.3. Key Trends

    12.4. Western Europe Market Forecast

        12.4.1. Market Value (US$ Mn) Forecast, By Country

            12.4.1.1. K. Absolute $ Opportunity

            12.4.1.2. Germany Absolute $ Opportunity

            12.4.1.3. France Absolute $ Opportunity

            12.4.1.4. Spain Absolute $ Opportunity

            12.4.1.5. Italy Absolute $ Opportunity

            12.4.1.6. Nordic Countries Absolute $ Opportunity

            12.4.1.7. Rest of Western Europe Absolute $ Opportunity

        12.4.2. Market Value (US$ Mn) Forecast, By Product Type

            12.4.2.1. Monoclonal antibodies 

            12.4.2.2. Polyclonal antibodies 

            12.4.2.3. Antibody-drug complexes (ADCs) 

        12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            12.4.3.1. Cardiovascular diseases 

            12.4.3.2. CNS disorders 

            12.4.3.3. Cancer

            12.4.3.4. Autoimmune Disorders

        12.4.4. Market Value (US$ Mn) Forecast, By End User

            12.4.4.1. Hospitals

            12.4.4.2. Long-term Care Facilities

            12.4.4.3. Research institutes

        12.4.5. Market Attractiveness Analysis

            12.4.5.1. By Country

            12.4.5.2. By Product Type

            12.4.5.3. By End User 

            12.4.5.4. By Disease Indication

        12.4.6. Drivers & Restraints: Impact Analysis

13. Eastern Europe Antibodies Market Analysis

    13.1. Introduction

        13.1.1. Y-o-Y Growth Projections, By Country

        13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    13.2. Key Regulations

    13.3. Key Trends

    13.4. Eastern Europe Market Forecast

        13.4.1. Market Value (US$ Mn) Forecast, By Country

    13.5. Poland Absolute $ Opportunity

    13.6. Russia Absolute $ Opportunity

    13.7. Rest of Eastern Europe Absolute $ Opportunity

        13.7.1. Market Value (US$ Mn) Forecast, By Product Type

            13.7.1.1. Monoclonal antibodies 

            13.7.1.2. Polyclonal antibodies 

            13.7.1.3. Antibody-drug complexes (ADCs) 

        13.7.2. Market Value (US$ Mn) Forecast, By Disease Indication

            13.7.2.1. Cardiovascular diseases 

            13.7.2.2. CNS disorders 

            13.7.2.3. Cancer

            13.7.2.4. Autoimmune Disorders

        13.7.3. Market Value (US$ Mn) Forecast, By End User

            13.7.3.1. Hospitals

            13.7.3.2. Long-term Care Facilities

            13.7.3.3. Research institutes

        13.7.4. Market Attractiveness Analysis

            13.7.4.1. By Country

            13.7.4.2. By Product Type

            13.7.4.3. By End User 

            13.7.4.4. By Disease Indication

        13.7.5. Drivers & Restraints: Impact Analysis

14. Asia Pacific Excl. Japan Antibodies Market Analysis

    14.1. Introduction

        14.1.1. Y-o-Y Growth Projections, By Country

        14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    14.2. Key Regulations

    14.3. Key Trends

    14.4. Asia Pacific Excl. Japan Market Forecast

        14.4.1. Market Value (US$ Mn) Forecast, By Country

            14.4.1.1. China Absolute $ Opportunity

            14.4.1.2. India Absolute $ Opportunity

            14.4.1.3. ASEAN Absolute $ Opportunity

            14.4.1.4. Australia & New Zealand Absolute $ Opportunity

            14.4.1.5. Rest of APEJ Absolute $ Opportunity

        14.4.2. Market Value (US$ Mn) Forecast, By Product Type

            14.4.2.1. Monoclonal antibodies 

            14.4.2.2. Polyclonal antibodies 

            14.4.2.3. Antibody-drug complexes (ADCs) 

        14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            14.4.3.1. Cardiovascular diseases 

            14.4.3.2. CNS disorders 

            14.4.3.3. Cancer

            14.4.3.4. Autoimmune Disorders

        14.4.4. Market Value (US$ Mn) Forecast, By End User

            14.4.4.1. Hospitals

            14.4.4.2. Long-term Care Facilities

            14.4.4.3. Research institutes

        14.4.5. Market Attractiveness Analysis

            14.4.5.1. By Country

            14.4.5.2. By Product Type

            14.4.5.3. By End User 

            14.4.5.4. By Disease Indication

        14.4.6. Drivers & Restraints: Impact Analysis

15. Japan Antibodies Market Analysis

    15.1. Introduction

    15.2. Key Regulations

    15.3. Key Trends

    15.4. Japan Market Forecast

        15.4.1. Market Value (US$ Mn) Forecast, By Product Type

            15.4.1.1. Monoclonal antibodies 

            15.4.1.2. Polyclonal antibodies 

            15.4.1.3. Antibody-drug complexes (ADCs) 

        15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication

            15.4.2.1. Cardiovascular diseases 

            15.4.2.2. CNS disorders 

            15.4.2.3. Cancer

            15.4.2.4. Autoimmune Disorders

        15.4.3. Market Value (US$ Mn) Forecast, By End User

            15.4.3.1. Hospitals

            15.4.3.2. Long-term Care Facilities

            15.4.3.3. Research institutes

        15.4.4. Market Attractiveness Analysis

            15.4.4.1. By Product Type

            15.4.4.2. By End User 

            15.4.4.3. By Disease Indication

        15.4.5. Drivers & Restraints: Impact Analysis

16. MEA Antibodies Market Analysis

    16.1. Introduction

        16.1.1. Y-o-Y Growth Projections, By Country

        16.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    16.2. Key Regulations

    16.3. Key Trends

    16.4. MEA Market Forecast

        16.4.1. Market Value (US$ Mn) Forecast, By Country

            16.4.1.1. GCC Countries Absolute $ Opportunity

            16.4.1.2. South Africa Absolute $ Opportunity

            16.4.1.3. North Africa Absolute $ Opportunity

            16.4.1.4. Rest of MEA Absolute $ Opportunity

        16.4.2. Market Value (US$ Mn) Forecast, By Product Type

            16.4.2.1. Monoclonal antibodies 

            16.4.2.2. Polyclonal antibodies 

            16.4.2.3. Antibody-drug complexes (ADCs) 

        16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            16.4.3.1. Cardiovascular diseases 

            16.4.3.2. CNS disorders 

            16.4.3.3. Cancer

            16.4.3.4. Autoimmune Disorders

        16.4.4. Market Value (US$ Mn) Forecast, By End User

            16.4.4.1. Hospitals

            16.4.4.2. Long-term Care Facilities

            16.4.4.3. Research institutes

        16.4.5. Market Attractiveness Analysis

            16.4.5.1. By Country

            16.4.5.2. By Product Type

            16.4.5.3. By End User 

            16.4.5.4. By Disease Indication

        16.4.6. Drivers & Restraints: Impact Analysis

17. Competition Landscape

    17.1. Company Share Analysis

    17.2. Competition Dashboard

    17.3. Company Profiles Inclusions

        17.3.1. Revenue

        17.3.2. Products/Brand Offerings

        17.3.3. Key developments

        17.3.4. SWOT Analysis

    17.4. Company Profiled

        17.4.1. Novartis AG 

        17.4.2. Hoffmann-La Roche Ltd.

        17.4.3. Johnson & Johnson Services, Inc. 

        17.4.4. Takeda Pharmaceutical Company Limited

        17.4.5. Amgen Inc.

        17.4.6. Biogen Inc. 

        17.4.7. Bristol-Myers Squibb Company

        17.4.8. AbbVie Inc. 

        17.4.9. Sanofi

        17.4.10. Eli Lilly and Co.

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables
  1. Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  2. Global Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  3. Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  4. Global Antibodies Market Value (US$ Mn) Analysis and Forecast By Region, 2021 – 2031
  5. North America Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
  6. North America Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  7. North America Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  8. North America Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  9. Latin America Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
  10. Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  11. Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  12. Latin America Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  13. Western Europe Antibodies Market Value (US$ Bn) Forecast By Country, 2021 – 2031
  14. Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  15. Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  16. Western Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  17. Eastern Europe Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
  18. Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  19. Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  20. Eastern Europe Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  21. APEJ Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
  22. APEJ Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031 APEJ Antibodies Market BPS Analysis, Market
  23. APEJ Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  24. Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  25. Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  26. Japan Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
  27. MEA Antibodies Market Value (US$ Mn) Forecast By Country, 2021 – 2031
  28. MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031
  29. MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031
  30. MEA Antibodies Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts
  1. Global Antibody Market Split By Drug Type (2021)
  2. Global Antibody Market Split By Disease Indication (2021)
  3. Global Antibody Market Split By End User (2021)
  4. Global Antibody Market Split By By Region (2021)
  5. Global Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  6. Global Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  7. Global Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  8. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Monoclonal Antibodies Segment, 2021 – 2031
  9. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Polyclonal Antibodies Segment, 2021 – 2031
  10. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
  11. Global Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  12. Global Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  13. Global Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  14. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
  15. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
  16. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
  17. Global Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  18. Global Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  19. Global Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  20. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
  21. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
  22. Global Antibodies Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
  23. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
  24. Global Antibodies Market BPS Analysis (%) By Region, 2021 & 2031
  25. Global Antibodies Market Attractiveness Analysis By Region, 2021 – 2031
  26. Global Antibodies Market Y-o-Y growth (%) By Region, 2021 – 2031
  27. North America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  28. Latin America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  29. Global Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  30. Global Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  31. Global Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  32. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Monoclonal Antibodies Segment, 2021 – 2031
  33. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Polyclonal Antibodies Segment, 2021 – 2031
  34. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031
  35. Global Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  36. Global Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  37. Global Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  38. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031
  39. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031
  40. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031
  41. Global Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  42. Global Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  43. Global Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  44. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031
  45. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031
  46. Global Antibodies Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031
  47. Global Antibodies Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031
  48. Global Antibodies Market BPS Analysis (%) By Region, 2021 & 2031
  49. Global Antibodies Market Attractiveness Analysis By Region, 2021 – 2031
  50. Global Antibodies Market Y-o-Y growth (%) By Region, 2021 – 2031
  51. North America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  52. Latin America Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  53. Western Europe Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  54. Eastern Europe Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  55. APEJ Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  56. Japan  Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  57. MEA Antibodies Market Absolute $ Opportunity (US$ Bn), 2021 – 2031
  58. North America Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  59. North America Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  60. North America Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  61. North America Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  62. North America Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  63. North America Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  64. North America Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  65. North America Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  66. North America Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  67. North America Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  68. North America Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  69. North America Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  70. Latin America Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  71. Latin America Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  72. Latin America Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  73. Latin America Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  74. Latin America Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  75. Latin America Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  76. Latin America Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  77. Latin America Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  78. Latin America Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  79. Latin America Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  80. Latin America Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  81. Latin America Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  82. Western Europe Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  83. Western Europe Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  84. Western Europe Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  85. Western Europe Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  86. Western Europe Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  87. Western Europe Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  88. Western Europe Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  89. Western Europe Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  90. Western Europe Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  91. Western Europe Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  92. Western Europe Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  93. Western Europe Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  94. Eastern Europe Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  95. Eastern Europe Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  96. Eastern Europe Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  97. Eastern Europe Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  98. Eastern Europe Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  99. Eastern Europe Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  100. Eastern Europe Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  101. Eastern Europe Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  102. Eastern Europe Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  103. Eastern Europe Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  104. Eastern Europe Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  105. Eastern Europe Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  106. APEJ Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  107. APEJ Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  108. APEJ Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  109. APEJ Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  110. APEJ Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  111. APEJ Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  112. APEJ Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  113. APEJ Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  114. APEJ Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  115. Japan Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  116. Japan Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  117. Japan Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  118. Japan Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  119. Japan Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  120. Japan Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  121. Japan Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  122. Japan Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  123. Japan Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031
  124. MEA Antibodies Market BPS Analysis (%) By Country, 2021 & 2031
  125. MEA Antibodies Market Attractiveness Analysis By Country, 2021 – 2031
  126. MEA Antibodies Market Y-o-Y growth (%) By Country, 2021 – 2031
  127. MEA Antibodies Market BPS Analysis (%) By Drug Type, 2021 & 2031
  128. MEA Antibodies Market Attractiveness Analysis By Drug Type, 2021 – 2031
  129. MEA Antibodies Market Y-o-Y growth (%) By Drug Type, 2021 – 2031
  130. MEA Antibodies Market BPS Analysis (%) By End User, 2021 & 2031
  131. MEA Antibodies Market Attractiveness Analysis By End User, 2021 – 2031
  132. MEA Antibodies Market Y-o-Y growth (%) By End User, 2021 – 2031
  133. MEA Antibodies Market BPS Analysis (%) By Indication, 2021 & 2031
  134. MEA Antibodies Market Attractiveness Analysis By Indication, 2021 – 2031
  135. MEA Antibodies Market Y-o-Y growth (%) By Indication, 2021 – 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate